Russia’s new mRNA cancer vaccine ‘Enteromix’ shows 100% success in trials

In what medical experts are calling a potential game-changer in oncology, Russia’s newly developed mRNA cancer vaccine, Enteromix, has demonstrated 100 percent efficacy and safety in clinical trials.

If approved, the treatment could revolutionize cancer care and potentially save millions of lives worldwide.

Developed by the National Medical Research Radiology Centre in partnership with the Engelhardt Institute of Molecular Biology, Enteromix is now awaiting final clearance from Russia’s Ministry of Health.

Once authorized, it is set to become the world’s first personalized mRNA-based cancer vaccine available to the public.

Unlike chemotherapy and radiation, which often damage healthy cells alongside cancerous ones, Enteromix is designed to work with the body’s immune system. The vaccine “trains” immune cells to recognize and attack tumors, while also strengthening the body’s natural defenses.

READ ALSO: NAFDAC issues health alert over counterfeit cancer drug allegedly sourced from Nigeria

Researchers say Enteromix can shrink large tumors, destroy malignant cells, and prevent regrowth. A MedPath report noted that the vaccine deploys four harmless viruses to penetrate cancer cells and activate a stronger immune response.

“Borrowing from the same advanced technology used in COVID-19 vaccines, Enteromix is tailored to each patient,” scientists explained, emphasizing its personalized medicine approach.

The breakthrough was first presented at the St. Petersburg International Economic Forum (SPIEF 2025). Clinical trials involved 48 participants, and results showed consistent tumor suppression and, in some cases, complete tumor destruction.

Notably, patients experienced no serious side effects, a stark contrast to conventional cancer treatments that often leave patients debilitated.

According to RT India, trial participants tolerated the vaccine well, further supporting its safety profile.

Medical experts worldwide have long argued that a safe and effective cancer vaccine would mark one of the greatest advances in modern medicine. The strong trial results from Enteromix have ignited new hope among doctors, patients, and families.

If granted regulatory approval, Enteromix could soon become publicly available, marking a historic turning point in the global fight against cancer.